$6.85
+0.00%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$6.93
From 52W high−27.05%
Volume190951.00
Market cap$369.39M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataSep 18, 2026
Open
$6.93
From 52W high
−27.05%
Volume
190951.00
Market cap
$369.39M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−8.8x
P/E (TTM)
—
RSI (14)
55.5
MomentumView details →
1D Return
+0.00%
YTD Return
−14.47%
SummaryUpdated Jun 1, 2026
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Minneapolis, Minnesota. The company was formerly known as DiaMedica Inc. before changing its name in December 2016. DiaMedica focuses on developing novel treatments for neurological and kidney diseases, with its lead drug candidate DM199 currently in Phase 2 and Phase 2/3 clinical trials for stroke and kidney disease applications. The company went public in 2012 and has since expanded its clinical pipeline to include treatments for preeclampsia, representing a significant pivot into pregnancy-related conditions.
Similar companies
Latest newsMore news →
DiaMedica Therapeutics reported its second-quarter progress and financial results, highlighting advancement of DM199 in early-onset fetal growth restriction, preeclampsia, and acute ischemic stroke, and a cash runway expected to extend through 2027.40d agoDiaMedica Therapeutics dosed the first patients in a Phase 2 trial of DM199 for treating fetal growth restriction.89d ago